ONO-4685

Phase 1Small molecule

Ono Pharmaceutical Co. Ltd

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed or Refractory T Cell LymphomaActive, not recruiting

Relapsed or Refractory T Cell LymphomaPhase 1

Active, not recruiting

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Relapsed or Refractory T Cell Lymphoma

NCT05079282

Q2 2029

Phase 1Active, not recruiting

Relapsed or Refractory T Cell Lymphoma

NCT06547528

Clinical

Trials by Indication[1]

Relapsed or Refractory T Cell Lymphoma2 trials

An Open-label, Multi-center, Non-randomized Phase I Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT05079282·217 enrolled

An Open-label, Uncontrolled, Phase I Dose Escalation Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in Patients With Relapsed or Refractory T Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT06547528·108 enrolled

Single Ascending Dose1 trial

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD of ONO-4685 in Japanese and Caucasian Healthy Adult Male Subjects

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT04079062·78 enrolled

Efficacy1 trial

Safety, Tolerability, PK, PD and Preliminary Efficacy of ONO-4685

Completed· Ono Pharmaceutical Co. Ltd logo

Ono Pharmaceutical Co. Ltd·Phase 1·NCT05332704·33 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for ONO-4685. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ONO-4685 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ONO-4685. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ono Pharmaceutical Co. Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Ono Pharmaceutical Co. Ltd